Felipe Jens Montoro is a highly resourceful man and has a mark in the development of infrastructure. The government has heavily relied on his valuable insight before embarking on mega projects. This has made him chair various executive position in boards and corporations.

He was very instrumental in helping Brazil recovery after the economic recession that hit the country. He found out that some public corporate was going south following the government inability to allocate enough funds to keep them running. To combat this, he proposed that privatization would help salvage the situation and sure to his word this has brought a paradigm shift. This arrangement birthed the Public Private Partnership. More about Felipe Montoro Jens at ideamensch.com

Felipe Jens Montoro, recently observed that civil projects ranging from waterways, roads, to special daycare projects had stalled. He established that technical problems, land disputes, construction works withdrawing among other things was the cause of this interruption. However, over and above this he found budgetary, financial and poor planning to be at the epitome of the halt. He advised the government to review their expenditure and allocate more funds to the sector. In the same vein, the project should be well planned out to avoid such happening in future as it is draining the country financially considering the projects do not in any way benefit the public.

About Felipe Jens Montoro

Felipe Jens Montoro is a finance and infrastructure expert from Brazil. He is an elite member of the society having studied Spanish and History, has a degree in Business Administration from the FundaoGetlio Vargas and a Master’s degree in Health Promotion and Kinesiology. He is also an alumnus of Oregon University, UC Santa Barbra and American Garvin School. Mr. Montoro has worked with many companies such as the Enel Group S.P.A, Maranon Energia SA, ConcessionariaInteroceanica Sur Tramo, Fonte Nova Negocios e Participacoes among others. Presently, he is the CEO of EnergiparCaptacao S.A.

Visit: http://maringa.odiario.com/politica/2018/03/veja-com-felipe-montoro-jens-cidade-mineira-investe-em-ppp-para-estimular-o-lazer-e-a-pratica-de-atividades-fisicas-da-populacao/2476577/

November 26, 2018 · Business, Company, Entrepreneur · (No comments)

Since being launched 20 years ago Fortress Investment Group has been a pioneer in the industry. It was initially founded as a private equity firm. Fortress has proven itself as a trendsetter on several occasions, specifically back in 2007 when it became the first large-scale private equity firm to go public on the New York Stock Exchange. The initial public offering (IOP) made the company a household name.

Fortress has continued to evolve since then, becoming a diversified global investment management firm responsible for well over $40 billion worth of assets for a little less than 1,800 investors in private equity, permanent capital vehicles, and hedge funds. Though the investment strategy it hangs its hat on is risky it is also highly successful and beneficial for investors down the line. With its base of operations located in New York it possesses an employee base nearing 1,000 individuals. Read this article at bizjournals.com to learn more about Peter Briger.

The investment group has three principals, who are Randal Nardone, and Wes Edens, and San Francisco-based Peter Briger.

With all the ups-and-downs Fortress Investment Group has been through as a company it has picked up in depth knowledge of managing mergers and acquisitions. Its team members have developed strong bonds with a variety of corporate board members, management professionals, and other corporate stakeholders. Its expertise also means that its specializes in capital markets. Especially as it pertains to securing financing via debt and equity markets.

Before Peter Briger joined Fortress Investment Group in 2002 he worked as a partner at Goldman, Sachs for 15 years. His main duty at Fortress is to oversee the Fortress Credit division. Peter Briger is a very prominent business professional who is also a member of the Forbes 400.

As a Princeton grad Peter Briger is a member of the Ivy League school’s investment company. Peter attended the Wharton School of Business at the University of Pennsylvania as well. He graduated with a master’s degree in Business Administration.

Learn more: https://entrepreneurs.princeton.edu/people/peter-briger-jr-%E2%80%9886

 

October 30, 2018 · Business, Business Leaders · (No comments)

Jeffrey Aronin has been a big name in the pharmaceutical industry for many years. Currently the CEO of Paragon Biosciences, he has had a hand in the start-up process of different portions of this company as well as many others over the past 20 years. Having completed his education at Northern Illinois University and DePaul University Jeffrey Aronin obtained a Bachelors and Sciences and an M.B.A., respectively. During his schooling, Aronin was mentored by a physician who was responsible for treating a child who experienced many seizures. Over the course of time, it was determined that the boy would not be an ideal candidate for traditional forms of treatment and medication for his ailment due to his age as well as other factors. It was during this time, and his experience with this patient specifically, that Jeffrey Aronin developed his passion for helping those in need who dealt with rare diseases on a daily basis. As within the case that began his passion, Aronin uses his position in the scientific community to find alternate forms of medicine to give a chance to those who may not have had one otherwise. (prweb)

Paragon Biosciences is made up of a group of different companies including Castle Creek Pharma, Harmony Biosciences, Skyline Biosciences, and Emalex Biosciences. Due to the breath of the company, Jeffrey Aronin is able to utilize many individuals in his pursuit of providing care to those in need. An example of his dedication to his goals is made clear when considering the fact that Paragon has invested over $45 million in parasitical compounds and the building of several subsidiary companies aimed at the treatment of rare conditions since October of 2017.

Viewed by many in the pharmaceutical and biosciences communities as being a man who has earned himself great honor, Aronin states that the most important thing to him is that he is in a position that allows him to do what he believes in: help those in need.